ABSTRACT
BACKGROUND: Iron is one of the key microelements in the mammalian body and is the most abundant metal in the brain. Iron, a very important chemical element in the body of mammals, is the most abundant metal in the brain. It participates in many chemical reactions taking place in the central nervous system acting as a cofactor in key enzymatic reactions involved in neurotransmitter synthesis and degradation, dendritic arborization, and myelination. Moreover, iron accumulation in the brain has been implicated in the pathogenesis of neurogenerative disorders. MATERIAL AND METHODS: The aim of our study was to assess the influence of iron administered orally (30 mg/kg) to rats in the neonatal period (p12-p14) by testing the performance of rats in the open field and social interaction tests, and by evaluating the recognition memory, monoamine levels in some brain structures, and BDNF mRNA expression. The behavioral and biochemical tests were performed in adult p88-p92 rats. RESULTS: Iron administered to rats in the neonatal period induced long-term deficits in behavioral tests in adult rats. It reduced the exploratory activity in the open field test. In the social interaction test, it induced deficits in the parameters studied, and decreased memory retention. Moreover, iron changed the brain monoamine levels in some studied brain structures and decreased the expression of BDNF mRNA in the hippocampus. CONCLUSIONS: All earlier and our present results indicated that iron administered to rats in the neonatal period induced an increase in oxidative stress which resulted in a change in the brain monoamine levels and decreased BDNF mRNA expression which may play a role in iron-induced memory impairment in adult rats.
ABSTRACT
BACKGROUND: Phencyclidine, an NMDA receptor antagonist, is frequently used to model behavioral and neurochemical changes correlated with schizophrenia in laboratory animals. The present study aimed to examine the effects of repeated administration of phencyclidine during early postnatal development on the contents of glutathione and sulfur-containing amino acids, as well as the activity of antioxidant enzymes in the brain of 12-day-old rats, and schizophrenia-like symptoms in adulthood. METHODS: Male Sprague-Dawley pups were administered phencyclidine (10 mg/kg) or saline subcutaneously on the postnatal days p2, p6, p9 and p12. In 12-day-old pups, 4 h after the last dose of phencyclidine, the levels of glutathione, cysteine, methionine, and homocysteine, and the enzymatic activity of superoxide dismutase (SOD), glutathione peroxidase (GPx), and glutathione reductase (GR) were measured in the frontal cortex, hippocampus, and striatum. In 70-72-day-old rats, schizophrenia-like symptoms were assessed using behavioral tests. RESULTS: Biochemical data showed that perinatal phencyclidine treatment significantly reduced glutathione and cysteine levels in all brain structures studied, methionine was diminished in the striatum, and homocysteine in both the frontal cortex and striatum. GR activity was increased in the frontal cortex while SODactivity was decreased in the hippocampus. Behaviorally, perinatal phencyclidine induced long-term deficits in social and cognitive function and a decrease in locomotor activity assessed as the time of walking. Finally, perinatal treatment with phencyclidine resulted in a significant reduction in body weight gain over time. CONCLUSION: Our research provides further evidence for the usefulness of the phencyclidine-induced neurodevelopmental model of schizophrenia for studying the pathogenesis of schizophrenia.
Subject(s)
Brain , Glutathione , Phencyclidine , Rats, Sprague-Dawley , Receptors, N-Methyl-D-Aspartate , Schizophrenia , Animals , Phencyclidine/toxicity , Phencyclidine/pharmacology , Schizophrenia/metabolism , Schizophrenia/drug therapy , Schizophrenia/chemically induced , Glutathione/metabolism , Male , Receptors, N-Methyl-D-Aspartate/metabolism , Rats , Brain/metabolism , Brain/drug effects , Brain/growth & development , Amino Acids, Sulfur/metabolism , Behavior, Animal/drug effects , Disease Models, Animal , Animals, NewbornABSTRACT
Preclinical and clinical studies have shown that the antipsychotic drug aripiprazole and the antioxidant N-acetylcysteine have unique biological properties. The aim of the study was to investigate, in a rat model of schizophrenia, the effects of chronic administration of these drugs on schizophrenia-like behaviors and anaerobic cysteine metabolism in the hippocampus (HIP). The schizophrenia-type changes were induced in Sprague-Dawley rats by repeated administration of the glutathione synthesis inhibitor l-butionine-(S,R)-sulfoximine in combination with the dopamine reuptake inhibitor GBR 12909 in the early postnatal period. Adult model rats were chronically treated with aripiprazole (0.3 mg·kg-1 , i.p.) or N-acetylcysteine (30 mg·kg-1 , orally), and their effects on schizophrenia-like behaviors were assessed using the social interaction test and novel object recognition test. In the HIP, the level of anaerobic cysteine metabolites, H2 S, and bound sulfane sulfur were determined by a fluorescence method, while the expression of H2 S-synthetizing enzymes: cystathionine ß-synthase (CBS) and mercaptopyruvate sulfurtransferase (MST) by western blot. Long-term treatment with aripiprazole or N-acetylcysteine reversed social and cognitive deficits and reduced the exploratory behaviors. In the HIP of 16-day-old model pups, H2 S levels and MST protein expression were significantly decreased. In adult model rats, H2 S levels remained unchanged, bound sulfane sulfur significantly increased, and the expression of CBS and MST slightly decreased. The studied drugs significantly reduced the level of bound sulfane sulfur and the expression of tested enzymes. The reduction in bound sulfane sulfur level coincided with the attenuation of exploratory behavior, suggesting that modulation of anaerobic cysteine metabolism in the HIP may have therapeutic potential in schizophrenia.
Subject(s)
Acetylcysteine , Schizophrenia , Rats , Animals , Acetylcysteine/pharmacology , Cysteine/metabolism , Aripiprazole/adverse effects , Schizophrenia/chemically induced , Schizophrenia/drug therapy , Schizophrenia/metabolism , Anaerobiosis , Rats, Sprague-Dawley , Sulfur/metabolism , Hippocampus/metabolismABSTRACT
Recent studies suggest that impaired glutathione synthesis and distorted dopaminergic transmission are important factors in the pathophysiology of schizophrenia. In the present study, on the postnatal days p5-p16, male pups were treated with the inhibitor of glutathione synthesis, L-buthionine-(S,R)- sulfoximine (BSO, 3.8 or 7.6 mmol/kg), and the dopamine uptake inhibitor, GBR 12,909 (5 mg/kg) alone or in combination, and prepulse inhibition of the acoustic startle response (PPI) was evaluated in adult 90-day-old rats. Moreover, the monoamine levels in the cortex and hippocampus of 16-day-old rats or 91-day-old rats were measured. The present results showed that administration of BSO at 3.8 mmol/kg led to a decreasing tendency in PPI for all tested prepulse intensities. In contrast, a combined treatment with BSO in both studied doses and GBR 12,909 did not induce significant deficits in PPI. Moreover, the results of biochemical studies indicated that treatment with BSO or GBR 12,909 alone induced a weak increase in the activity of dopaminergic, serotonergic, and noradrenergic systems in the frontal cortex and hippocampus of 16-day-old rats and 91-day-old rats. However, the combined administration of both substances allowed for maintaining the normal activity of monoaminergic systems in the rat brain. The most significant changes in the functioning of monoaminergic systems were observed in the frontal cortex of 16-day-old rats. Therefore, it seems that the frontal cortex of rat puppies is most sensitive to glutathione deficiencies resulting in increased oxidative stress in neurons. As a result, it can lead to cognitive and memory impairment.
Subject(s)
Prepulse Inhibition , Reflex, Startle , Animals , Brain , Dopamine/pharmacology , Glutathione/pharmacology , Male , Rats , Rats, Sprague-DawleyABSTRACT
Treatment of negative symptoms and cognitive disorders in patients with schizophrenia is still a serious clinical problem. The aim of our study was to compare the efficacy of chronic administration of the atypical antipsychotic drug aripiprazole (7-{4-[4-(2,3-dichlorophenyl)-1-piperazinyl] butoxy}-3,4-dihydro-2(1H)-quinolinone; ARI) and the well-known antioxidant N-acetylcysteine (NAC) both in alleviating schizophrenia-like social and cognitive deficits and in reducing the decreases in the levels of the brain-derived neurotrophic factor (BDNF) in the prefrontal cortex (PFC) and hippocampus (HIP) of adult Sprague-Dawley rats, that have been induced by chronic administration of the model compound L-buthionine-(S, R)-sulfoximine (BSO) during the early postnatal development (p5-p16). ARI was administered at doses of 0.1 and 0.3 mg/kg while NAC at doses of 10 and 30 mg/kg, alone or in combination. Administration of higher doses of ARI or NAC alone, or co-treatment with lower, ineffective doses of these drugs significantly improved social and cognitive performance as assessed in behavioral tests. Both doses of NAC and 0.3 mg/kg of ARI increased the expression of BDNF mRNA in the PFC, while all doses of these drugs and their combinations enhanced the levels of BDNF protein in this brain structure. In the HIP, only 0,3 mg/kg ARI increased the levels of both BDNF mRNA and its protein. These data show that in the rat BSO-induced neurodevelopmental model of schizophrenia, ARI and NAC differently modulated BDNF levels in the PFC and HIP.
Subject(s)
Acetylcysteine/pharmacology , Aripiprazole/pharmacology , Brain-Derived Neurotrophic Factor/metabolism , Cognition/drug effects , Hippocampus/drug effects , Prefrontal Cortex/drug effects , Schizophrenia/drug therapy , Animals , Antipsychotic Agents/pharmacology , Behavior, Animal/drug effects , Cognition Disorders/drug therapy , Cognition Disorders/metabolism , Disease Models, Animal , Female , Hippocampus/metabolism , Prefrontal Cortex/metabolism , Pregnancy , Quinolones/pharmacology , Rats , Rats, Sprague-Dawley , Schizophrenia/metabolism , Social BehaviorABSTRACT
BACKGROUND: Preclinical and clinical studies have indicated that impaired endogenous synthesis of glutathione during early postnatal development plays a significant role in the pathophysiology of schizophrenia. Moreover, some studies have suggested that antidepressants are able to increase the activity of atypical antipsychotics which may efficiently improve the treatment of negative and cognitive symptoms of schizophrenia. METHODS: In the present study, we investigated the influence of repeated co-treatment with escitalopram and aripiprazole on the schizophrenia-like behavior and BDNF mRNA expression in adult rats exposed to glutathione deficit during early postnatal development. Male pups between the postnatal days p5-p16 were treated with the inhibitor of glutathione synthesis, BSO (L-buthionine-(S,R)-sulfoximine) and the dopamine uptake inhibitor, GBR 12,909 alone or in combination. Escitalopram and aripiprazole were given repeatedly for 21 days before the tests. On p90-92 rats were evaluated in the behavioral and biochemical tests. RESULTS: BSO given alone and together with GBR 12,909 induced deficits in the studied behavioral tests and decreased the expression of BDNF mRNA. Repeated aripiprazole administration at a higher dose reversed these behavioral deficits. Co-treatment with aripiprazole and an ineffective dose of escitalopram also abolished the behavioral deficits in the studied tests. CONCLUSION: The obtained data indicated that the inhibition of glutathione synthesis in early postnatal development induced long-term deficits corresponding to schizophrenia-like behavior and decreased the BDNF mRNA expression in adult rats, and these behavioral deficits were reversed by repeated treatment with a higher dose of aripiprazole and also by co-treatment with aripiprazole and ineffective dose of escitalopram.
Subject(s)
Aripiprazole/pharmacology , Brain-Derived Neurotrophic Factor/genetics , Escitalopram/pharmacology , Schizophrenia/drug therapy , Animals , Animals, Newborn , Antipsychotic Agents/administration & dosage , Antipsychotic Agents/pharmacology , Aripiprazole/administration & dosage , Behavior, Animal/drug effects , Brain/drug effects , Brain/growth & development , Disease Models, Animal , Dose-Response Relationship, Drug , Drug Therapy, Combination , Escitalopram/administration & dosage , Glutathione/deficiency , Male , RNA, Messenger/metabolism , Rats , Rats, Sprague-Dawley , Schizophrenia/physiopathology , Selective Serotonin Reuptake Inhibitors/administration & dosage , Selective Serotonin Reuptake Inhibitors/pharmacologyABSTRACT
Growing body of evidence points to dysregulation of redox status in the brain as an important factor in the pathogenesis of schizophrenia. The aim of our study was to evaluate the effects of l-buthionine-(S,R)-sulfoximine (BSO), a glutathione (GSH) synthesis inhibitor, and 1-[2-Bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine dihydrochloride (GBR 12909), a dopamine reuptake inhibitor, given alone or in combination, to Sprague-Dawley pups during early postnatal development (p5-p16), on the time course of the onset of schizophrenia-like behaviors, and on the expression of brain-derived neurotrophic factor (BDNF) mRNA and its protein in the prefrontal cortex (PFC) and hippocampus (HIP) during adulthood. BSO administered alone decreased the levels of BDNF mRNA and its protein both in the PFC and HIP. Treatment with the combination of BSO + GBR 12909 also decreased BDNF mRNA and its protein in the PFC, but in the HIP, only the level of BDNF protein was decreased. Schizophrenia-like behaviors in rats were assessed at three time points of adolescence (p30, p42-p44, p60-p62) and in early adulthood (p90-p92) using the social interaction test, novel object recognition test, and open field test. Social and cognitive deficits first appeared in the middle adolescence stage and continued to occur into adulthood, both in rats treated with BSO alone or with the BSO + GBR 12909 combination. Behavior corresponding to positive symptoms in humans occurred in the middle adolescence period, only in rats treated with BSO + GBR 12909. Only in the latter group, amphetamine exacerbated the existing positive symptoms in adulthood. Our data show that rats receiving the BSO + GBR 12909 combination in the early postnatal life reproduced virtually all symptoms observed in patients with schizophrenia and, therefore, can be considered a valuable neurodevelopmental model of this disease.
Subject(s)
Brain-Derived Neurotrophic Factor/metabolism , Cerebral Cortex/pathology , Glutathione/deficiency , Hippocampus/pathology , Neurodevelopmental Disorders/pathology , Schizophrenia/pathology , Animals , Behavior, Animal , Brain-Derived Neurotrophic Factor/genetics , Cerebral Cortex/metabolism , Hippocampus/metabolism , Male , Neurodevelopmental Disorders/etiology , Neurodevelopmental Disorders/metabolism , Rats , Rats, Sprague-Dawley , Schizophrenia/etiology , Schizophrenia/metabolismABSTRACT
According to preclinical and clinical studies, the antidepressant-induced increase in the activity of atypical antipsychotics may efficiently improve the treatment of negative and some cognitive symptoms of schizophrenia. In the present study, we aimed to evaluate the effects of the antidepressants escitalopram and mirtazapine and the atypical antipsychotic drug aripiprazole, administered separately or in combination, on the MK-801-induced deficits in the recognition memory test and on the extracellular levels of monoamines and their metabolites in the rat frontal cortex. Based on the results of the behavioral tests, co-treatment with an ineffective dose of aripiprazole (0.1 mg/kg) and escitalopram (2.5 and 5 mg/kg) or mirtazapine (5 mg/kg) abolished the deficits evoked by MK-801 in the novel object recognition test, and those effects were blocked by the 5-HT1A receptor antagonist (WAY 100,635) or the dopamine D1 receptor antagonist (SCH 23,390). Moreover, co-treatment with aripiprazole (0.3 mg/kg) and escitalopram (5 mg/kg) significantly increased the levels of noradrenaline and serotonin, decreased the level of its metabolite, and did not alter level of dopamine, but decreased the levels of its metabolites. In addition, co-treatment with aripiprazole (0.3 mg/kg) and mirtazapine (10 mg/kg) significantly increased the level of noradrenaline, did not change the levels of dopamine and serotonin, but increased the levels of their metabolites. Based on these results, the increase in the extracellular levels of noradrenaline or serotonin in the cortex induced by co-treatment with an antidepressant and aripiprazole may be very important for the pharmacotherapy of negative and some cognitive symptoms of schizophrenia.
Subject(s)
Antidepressive Agents/pharmacology , Aripiprazole/pharmacology , Biogenic Monoamines/metabolism , Frontal Lobe/drug effects , Memory Disorders/drug therapy , Recognition, Psychology/drug effects , Animals , Antidepressive Agents/therapeutic use , Aripiprazole/therapeutic use , Benzazepines/pharmacology , Citalopram/pharmacology , Citalopram/therapeutic use , Dizocilpine Maleate , Dopamine Antagonists/pharmacology , Frontal Lobe/metabolism , Memory Disorders/chemically induced , Memory Disorders/metabolism , Piperazines/pharmacology , Pyridines/pharmacology , Rats , Serotonin Antagonists/pharmacologyABSTRACT
The aim of the present study was to assess the effects of l-buthionine-(S,R)-sulfoximine (BSO), a glutathione (GSH) synthesis inhibitor, and GBR 12909, a dopamine reuptake inhibitor, administered alone or in combination to Sprague-Dawley rats during early postnatal development (p5-p16), on the levels of reactive oxygen species (ROS), lipid peroxidation (LP) and the activities of antioxidant enzymes: superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx) and glutathione disulfide reductase (GR) in peripheral tissues (liver, kidney) and selected brain structures (prefrontal cortex, PFC; hippocampus, HIP; and striatum, STR) of 16-day-old rats. The studied parameters were analyzed with reference to the content of GSH and sulfur amino acids, methionine (Met) and cysteine (Cys) described in our previous study. This analysis showed that treatment with a BSO + GBR 12909 combination caused significant decreases in the lipid peroxidation levels in the PFC and HIP, in spite of there being no changes in ROS. The reduction of lipid peroxidation indicates a weakening of the oxidative power of the cells, and a shift in balance in favor of reducing processes. Such changes in cellular redox signaling in the PFC and HIP during early postnatal development may result in functional changes in adulthood.
ABSTRACT
Impaired glutathione (GSH) synthesis and dopaminergic transmission are important factors in the pathophysiology of schizophrenia. Our research aimed to assess the effects of l-buthionine-(S,R)-sulfoximine (BSO), a GSH synthesis inhibitor, and GBR 12909, a dopamine reuptake inhibitor, administered alone or in combination, to Sprague-Dawley rats during early postnatal development (p5-p16), on the levels of GSH, sulfur amino acids, global DNA methylation, and schizophrenia-like behavior. GSH, methionine (Met), homocysteine (Hcy), and cysteine (Cys) contents were determined in the liver, kidney, and in the prefrontal cortex (PFC) and hippocampus (HIP) of 16-day-old rats. DNA methylation in the PFC and HIP and schizophrenia-like behavior were assessed in adulthood (p90-p93). BSO caused the tissue-dependent decreases in GSH content and alterations in Met, Hcy, and Cys levels in the peripheral tissues and in the PFC and HIP. The changes in these parameters were accompanied by alterations in the global DNA methylation in the studied brain structures. Parallel to changes in the global DNA methylation, deficits in the social behaviors and cognitive functions were observed in adulthood. Only BSO + GBR 12909-treated rats exhibited behavioral alterations resembling positive symptoms in schizophrenia patients. Our results suggest the usefulness of this neurodevelopmental model for research on the pathomechanism of schizophrenia.
Subject(s)
Amino Acids, Sulfur/deficiency , Buthionine Sulfoximine/adverse effects , Glutathione/deficiency , Piperazines/adverse effects , Schizophrenia/chemically induced , Animals , DNA Methylation/drug effects , Disease Models, Animal , Homeostasis , Male , Rats , Rats, Sprague-Dawley , Schizophrenia/genetics , Schizophrenia/metabolismABSTRACT
BACKGROUND: Schizophrenia is a chronic, most devastating psychiatric illness that impairs mental and social functioning. A few clinical reports have suggested that antidepressant drugs are able to augment the activity of atypical antipsychotic drugs, thus effectively improving treatment of some negative symptoms of schizophrenia. METHODS: The aim of the present study was to investigate the effect of the antidepressant escitalopram or mirtazapine and aripiprazole (an atypical antipsychotic), given separately or jointly, on the deficits induced by MK-801(a noncompetitive N-methyl-d-aspartate receptor antagonist) in the social interaction test in male Sprague-Dawley rats. The social interaction was measured for 10 min, starting 4 h after MK-801 (0.1 mg/kg) administration. Antidepressants and aripiprazole were given 60 and 30 min before the test, respectively. WAY 100635 (a 5-HT1A antagonist) and SCH 23390 (a dopamine D1 antagonist) were give 20 min before the tests. RESULTS: The present results showed that MK-801 (0.1 mg/kg)-induced deficits in the social interaction test. Aripiprazole (0.1 and 0.3 mg/kg) reversed those effects. Co-treatment with an ineffective dose of aripiprazole (0.03 mg/kg) and escitalopram (5 and 10 mg/kg) or mirtazapine (5 mg/kg) abolished the deficits evoked by MK-801, and those effects were especially blocked by a 5-HT1A receptor antagonist (WAY 100635) or partly by dopamine D1 receptor antagonist (SCH 23390). CONCLUSIONS: The obtained results suggest that amelioration of the antipsychotic-like effect of aripiprazole by antidepressants in the MK-801-induced some negative symptoms of schizophrenia in rats may be associated with serotonin 5-HT1A and to a lesser degree with dopamine D1 receptors.
Subject(s)
Antidepressive Agents/therapeutic use , Antipsychotic Agents/therapeutic use , Aripiprazole/therapeutic use , Behavior, Animal/drug effects , Schizophrenia/drug therapy , Animals , Antidepressive Agents/administration & dosage , Antipsychotic Agents/administration & dosage , Aripiprazole/administration & dosage , Dizocilpine Maleate , Drug Therapy, Combination , Male , Motor Activity/drug effects , Rats, Sprague-Dawley , Schizophrenia/chemically induced , Social BehaviorABSTRACT
BACKGROUND: Preclinical and clinical studies have suggested a beneficial effect of combination treatment with atypical antipsychotic drugs and antidepressants (ADs) in schizophrenia and in drug-resistant depression. METHODS: In the present study, we investigated the effect of chronic administration of risperidone and ADs (escitalopram or mirtazapine), given separately or jointly on the extracellular levels of dopamine (DA) and serotonin (5-HT) in the rat frontal cortex. The animals were administered risperidone (0.2mg/kg) and escitalopram (5mg/kg) or mirtazapine (10mg/kg) repeatedly for 14days. The release of monoamines in the rat frontal cortex was evaluated using a microdialysis, and DA and 5-HT levels were assayed by HPLC. We also measured the locomotor activity, catalepsy and recognition memory in these rats. RESULTS: Chronic risperidone treatment (0.2mg/kg) increased the extracellular levels of DA and 5-HT. Co-treatment with risperidone and escitalopram (5mg/kg) or mirtazapine (10mg/kg) more efficiently increased the release of 5-HT but not DA in the rat frontal cortex, as compared to drugs given alone. Moreover, risperidone, escitalopram and mirtazapine given alone or in combination significantly decreased the locomotor activity and only mirtazapine increased the catalepsy evoked by risperidone. Combined treatment with risperidone and ADs impaired recognition memory in these rats. CONCLUSIONS: The obtained results suggest that chronic co-administration of risperidone and escitalopram or mirtazapine more efficiently increased 5-HT release in the rat frontal cortex as compared to drugs given alone and suggest that this effect may be of importance to the pharmacotherapy of schizophrenia and drug-resistant depression.
Subject(s)
Antidepressive Agents/pharmacology , Citalopram/pharmacology , Dopamine/metabolism , Frontal Lobe/drug effects , Frontal Lobe/metabolism , Mianserin/analogs & derivatives , Risperidone/pharmacology , Serotonin/metabolism , Animals , Antidepressive Agents/administration & dosage , Catalepsy/chemically induced , Drug Synergism , Locomotion/drug effects , Male , Mianserin/pharmacology , Mirtazapine , Rats , Recognition, Psychology/drug effects , Risperidone/administration & dosageABSTRACT
BACKGROUND: Atypical antipsychotic drugs have some efficacy in alleviating the negative and some cognitive symptoms of schizophrenia but those effects are small and mechanisms of this action are still unknown A few clinical reports have suggested that antidepressants (ADs), are able to augment the activity of atypical antipsychotic drugs. Thus, in the present study, we aimed to evaluate the effect of ADs, escitalopram (ESC) or mirtazapine (MIR) and aripiprazole (an atypical antipsychotic drug) given separately or jointly, on the MK-801-induced positive and cognitive symptoms of schizophrenia in mice. METHODS: The experiments were conducted on male Albino Swiss mice. ADs and aripiprazole were given 30min before MK-801 injection. Locomotor hyperactivity induced by MK-801 (0.3mg/kg) was measured for 30min, starting 30min after MK-801 administration. In the novel object recognition test, MK-801 (0.2mg/kg) was given 30min before the first introductory session. Memory retention was evaluated for 5min, starting 90min after the introductory session. RESULTS: Aripiprazole (0.3mg/kg) reduced the locomotor hyperactivity induced by MK-801(0.3mg/kg). Co-treatment with an inactive dose of aripiprazole and ESC or MIR inhibited the effect of MK-801. Moreover, MK-801 (0.2mg/kg) decreased the memory retention. Aripiprazole (0.3mg/kg) reversed that effect. Co-treatment with an inactive dose of aripiprazole and ESC or MIR abolished the deficit of object recognition memory induced by MK-801. CONCLUSIONS: The obtained results suggest that ADs may enhance the antipsychotic-like effect of aripiprazole in the animal tests used for evaluation of some positive and cognitive symptoms of schizophrenia.
Subject(s)
Antidepressive Agents/therapeutic use , Aripiprazole/therapeutic use , Citalopram/therapeutic use , Hyperkinesis/drug therapy , Memory Disorders/drug therapy , Mianserin/analogs & derivatives , Animals , Antipsychotic Agents/therapeutic use , Disease Models, Animal , Dizocilpine Maleate , Drug Synergism , Drug Therapy, Combination , Hyperkinesis/chemically induced , Male , Memory Disorders/complications , Mianserin/therapeutic use , Mice , Mirtazapine , Recognition, Psychology/drug effects , Schizophrenia/complications , Schizophrenia/drug therapy , Schizophrenic PsychologyABSTRACT
The effect of antidepressant drugs on tumor progress is very poorly recognized. The aim of the present study was to examine the effect of individual reactivity to stress and 24-day desipramine (DES) administration on the metastatic colonization of adenocarcinoma MADB 106 cells in the lungs of Wistar rats. Wistar rats were subjected to stress procedure according to the chronic mild stress (CMS) model of depression for two weeks and stress highly-sensitive (SHS) and stress non-reactive (SNR) rats were selected. SHS rats were more prone to cancer metastasis than SNR ones and chronic DES treatment further increased the number of lung metastases by 59% and 50% in comparison to vehicle-treated appropriate control rats. The increase in lung metastases was connected with DES-induced skew macrophage activity towards M2 functional phenotype in SHS and SNR rats. Moreover, during 24h after DES injection in healthy rats, the decreased number of TCD8+ and B cells in SHS and SNR rats as well as NK cell cytotoxic activity in SNR rats could be attributed to the lowered capacity to defend against cancer metastasis observed in chronic DES treated and tumor injected rats.
Subject(s)
Adenocarcinoma/complications , Adenocarcinoma/secondary , Desipramine/pharmacology , Lung Neoplasms/complications , Lung Neoplasms/secondary , Stress, Psychological/complications , Animals , Antidepressive Agents/pharmacology , Cell Line, Tumor , Lymphocyte Subsets/drug effects , Male , Rats , Rats, Inbred StrainsABSTRACT
BACKGROUND: Recently, several clinical studies have suggested a beneficial effect of a combination of antidepressants (ADs) with antipsychotic drugs in drug-resistant depression. Moreover, preclinical and clinical studies indicated a role of brain-derived neurotrophic factor (BDNF) in the pathology of depression, as well as in the mechanism of action of ADs. METHODS: In the present study, we investigated the effect of repeated administration of ADs, escitalopram, fluoxetine or mirtazapine and a low dose of risperidone (an atypical antipsychotic drug) given separately or in combination, on the mRNA and protein levels of BDNF or cAMP response element binding (p-CREB) in the hippocampus and frontal cortex of male Wistar rats. ADs were given repeatedly (once daily for 14 days), separately or in combination with a low dose of risperidone. The tissue for biochemical assays was dissected 24h after the last dose of ADs. RESULTS: The obtained results showed that repeated co-treatment with an inactive dose of risperidone and escitalopram or mirtazapine but not fluoxetine increased the BDNF mRNA expression in the hippocampus and frontal cortex. Moreover, combined treatment with an inactive dose risperidone and escitalopram elevated the protein levels of p-CREB in the frontal cortex. While, co-treatment with risperidone and fluoxetine or mirtazapine increased the protein levels of BDNF and p-CREB in both examined regions of the brain. CONCLUSIONS: Our present findings suggest that enhancement levels of BDNF may be essential for the therapeutic effect of co-treatment with ADs and a low dose risperidone in patients with drug-resistant depression.
Subject(s)
Antidepressive Agents/pharmacology , Brain-Derived Neurotrophic Factor/metabolism , Gene Expression Regulation/drug effects , RNA, Messenger/metabolism , Risperidone/pharmacology , Serotonin Antagonists/pharmacology , Animals , Antidepressive Agents/administration & dosage , Brain-Derived Neurotrophic Factor/genetics , Citalopram/administration & dosage , Citalopram/pharmacology , Drug Interactions , Fluoxetine/administration & dosage , Fluoxetine/pharmacology , Frontal Lobe/metabolism , Hippocampus/metabolism , Mianserin/administration & dosage , Mianserin/analogs & derivatives , Mianserin/pharmacology , Mirtazapine , RNA, Messenger/genetics , Rats , Rats, Wistar , Risperidone/administration & dosage , Serotonin Antagonists/administration & dosageABSTRACT
Several lines of evidence suggest that exposures to Endocrine Disrupting Chemicals (EDCs) such as pesticides increase the risks of neuropsychiatric disorders. Despite extended residual persistence of dichlorodiphenyltrichloroethane (DDT) in the environment, the mechanisms of perinatal actions of DDT that could account for adult-onset of depression are largely unknown. This study demonstrated the isomer-specific induction of depressive-like behavior and impairment of Htr1a/serotonin signaling in one-month-old mice that were prenatally exposed to DDT. The effects were reversed by the antidepressant citalopram as evidenced in the forced swimming (FST) and tail suspension (TST) tests in the male and female mice. Prenatally administered DDT accumulated in mouse brain as determined with gas chromatography and tandem mass spectrometry, led to global DNA hypomethylation, and altered the levels of methylated DNA in specific genes. The induction of depressive-like behavior and impairment of Htr1a/serotonin signaling were accompanied by p,p'-DDT-specific decrease in the levels of estrogen receptors i.e. ESR1 and/or GPER1 depending on sex. In contrast, o,p'-DDT did not induce depressive-like effects and exhibited quite distinct pattern of biochemical alterations that was related to aryl hydrocarbon receptor (AHR), its nuclear translocator ARNT, and ESR2. Exposure to o,p'-DDT increased AHR expression in male and female brains, and reduced expression levels of ARNT and ESR2 in the female brains. The evolution of p,p'-DDT-induced depressive-like behavior was preceded by attenuation of Htr1a and Gper1/GPER1 expression as observed in the 7-day-old mouse pups. Because p,p'-DDT caused sex- and age-independent attenuation of GPER1, we suggest that impairment of GPER1 signaling plays a key role in the propagation of DDT-induced depressive-like symptoms.
Subject(s)
Brain/drug effects , DDT/toxicity , DNA Methylation/drug effects , Endocrine Disruptors/toxicity , Estrogen Receptor alpha/antagonists & inhibitors , Prenatal Exposure Delayed Effects , Receptors, Estrogen/antagonists & inhibitors , Receptors, G-Protein-Coupled/antagonists & inhibitors , Animals , Antidepressive Agents, Second-Generation/therapeutic use , Behavior, Animal/drug effects , Brain/metabolism , Citalopram/therapeutic use , DDT/chemistry , Depression/chemically induced , Depression/drug therapy , Depression/metabolism , Endocrine Disruptors/chemistry , Estrogen Receptor alpha/metabolism , Female , Isomerism , Male , Mice , Neurons/drug effects , Neurons/metabolism , Neurotoxicity Syndromes/drug therapy , Neurotoxicity Syndromes/metabolism , Pregnancy , Random Allocation , Receptors, Estrogen/metabolism , Receptors, G-Protein-Coupled/metabolism , Sex Characteristics , Signal Transduction/drug effectsABSTRACT
BACKGROUND: Schizophrenia is a psychiatric disorder characterized by positive and negative symptoms often accompanied by depression and cognitive deficits. Positive symptoms, like delusions and hallucinations are caused by an excess of dopamine (DA) signaling and are treated with the second generation antipsychotic drugs. Negative symptoms of schizophrenia are represented by social withdrawal, apathy and blunted emotional response. It was demonstrated that co-administration of risperidone and selective serotonin reuptake inhibitors alleviated depressive symptoms and cognitive dysfunction in animal models of schizophrenia. Moreover, combination of fluoxetine or mirtazapine with risperidone increased DA and 5-hydroxytryptamine (5-HT) release in the rat frontal cortex more potently than either drug given separately. The present study aimed to investigate whether combination of risperidone and escitalopram is effective in increasing DA and 5-HT release. METHODS: The extracellular level of neurotransmitters in the rat frontal cortex and nucleus accumbens was examined using microdialysis in freely moving animals. The dialysate concentration of DA and 5-HT was assayed by HPLC. RESULTS: It was found that risperidone (0.2 and 1mg/kg) and escitalopram (5 and 10mg/kg) given together significantly increased cortical DA and 5-HT levels and were more efficient in enhancing neurotransmitter concentrations than any single-drug treatment. A similar effect on DA and 5-HT release was observed in the nucleus accumbens after administration of risperidone (1mg/kg) and escitalopram (5mg/kg). CONCLUSIONS: The present study demonstrates that co-administration of risperidone and escitalopram may be used to treat positive and negative symptoms of schizophrenia and will allow to minimize the drugs' side effects.
Subject(s)
Antipsychotic Agents/administration & dosage , Citalopram/administration & dosage , Risperidone/administration & dosage , Schizophrenia/drug therapy , Selective Serotonin Reuptake Inhibitors/administration & dosage , Animals , Antipsychotic Agents/adverse effects , Citalopram/adverse effects , Dopamine/metabolism , Drug Therapy, Combination , Male , Nucleus Accumbens/drug effects , Nucleus Accumbens/metabolism , Prefrontal Cortex/drug effects , Prefrontal Cortex/metabolism , Rats , Rats, Wistar , Risperidone/adverse effects , Schizophrenia/metabolism , Serotonin/metabolism , Treatment OutcomeABSTRACT
5-Methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT, 'foxy') is one of the most popular tryptamine hallucinogens in the illicit drug market. It produces serious adverse effects, but its pharmacological profile is not well recognized. In vitro data have shown that 5-MeO-DIPT acts as a potent serotonin transporter (SERT) inhibitor and displays high affinity at serotonin 5-HT1A, 5-HT2A, and 5-HT2C receptors. In this study, using microdialysis in freely moving rats, we examined the effect of 5-MeO-DIPT on dopamine (DA), serotonin (5-HT), and glutamate release in the rat striatum, nucleus accumbens, and frontal cortex. In search of a possible neurotoxic effect of 5-MeO-DIPT, we measured DA and 5-HT tissue content in the above rat brain regions and also determined the oxidative DNA damage with the comet assay. Moreover, we tested drug-elicited head-twitch response and a forepaw treading induced by 8-OH-DPAT. 5-MeO-DIPT at doses of 5, 10, and 20 mg/kg increased extracellular DA, 5-HT, and glutamate level but the differences in the potency were found between brain regions. 5-MeO-DIPT increased 5-HT and decreased 5-HIAA tissue content which seems to result from SERT inhibition. On the other hand, a decrease in DA, DOPAC, and HVA tissue contents suggests possible adaptive changes in DA turnover or damage of DA terminals by 5-MeO-DIPT. DNA single and double-strand breaks persisted up to 60 days after the treatment, indicating marked neurotoxicity of 5-MeO-DIPT. The induction of head-twitch response and potentiation of forepaw treading induced by 8-OH-DPAT indicate that hallucinogenic activity seems to be mediated through the stimulation of 5-HT2A and 5-HT1A receptors by 5-MeO-DIPT.
Subject(s)
5-Methoxytryptamine/analogs & derivatives , Corpus Striatum/drug effects , Frontal Lobe/drug effects , Hallucinogens/toxicity , Nucleus Accumbens/drug effects , 5-Methoxytryptamine/toxicity , 8-Hydroxy-2-(di-n-propylamino)tetralin/pharmacology , Amphetamines/pharmacology , Analysis of Variance , Animals , Corpus Striatum/metabolism , DNA Damage/drug effects , Dopamine/metabolism , Frontal Lobe/metabolism , Glutamic Acid/metabolism , Illicit Drugs/toxicity , Male , Microdialysis , Motor Activity/drug effects , Motor Activity/physiology , N-Methyl-3,4-methylenedioxyamphetamine/toxicity , Nucleus Accumbens/metabolism , Oxidative Stress/drug effects , Rats, Wistar , Serotonin/metabolismABSTRACT
BACKGROUND: Atypical antipsychotic drugs have some efficacy in alleviating the negative and some cognitive symptoms of schizophrenia but those effects are small and mechanisms of this action are still unknown. A few clinical reports have suggested that the antidepressant drugs, especially selective serotonin reuptake inhibitors (SSRI) are able to augment the activity of atypical antipsychotic drugs, thus effectively improving treatment of the negative and some cognitive symptoms of schizophrenia. METHODS: In the present study, we evaluated the effect of escitalopram (SSRI) and risperidone (an atypical antipsychotic drug), given separately or jointly, on the effect of MK-801 (a NMDA receptor antagonist) given before to the first introductory session, in the object recognition memory test. The mice were tested for the ability to discriminate between an old, familiar and a novel object. Escitalopram and risperidone were given 30min before MK-801, and MK-801 was administered 30min before the first introductory session. Memory retention was evaluated 90min after the introductory session. RESULTS: The obtained results showed that MK-801 (0.2mg/kg) decreased memory retention when given before the introductory session. Risperidone at a higher dose (0.1mg/kg) reversed that effect. Co-treatment with an ineffective dose of risperidone (0.01mg/kg) and escitalopram (5 or 10mg/kg) abolished the deficit of object recognition memory induced by MK-801. CONCLUSIONS: The obtained results suggest that escitalopram may enhance the antipsychotic-like effect of risperidone in the animal tests used for evaluation of some cognitive symptoms of schizophrenia.